The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?
Am J Respir Crit Care Med
.
2018 Apr 1;197(7):860-868.
doi: 10.1164/rccm.201709-1840PP.
Authors
Jason Weatherald
1
2
,
Athénaïs Boucly
3
4
5
,
Sandeep Sahay
6
,
Marc Humbert
3
4
5
,
Olivier Sitbon
3
4
5
Affiliations
1
1 Division of Respirology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada.
2
2 Libin Cardiovascular Institute of Alberta, Calgary, Alberta, Canada.
3
3 Université Paris-Sud, Faculté de Médecine, Université Paris-Saclay, Le Kremlin-Bicêtre, France.
4
4 Service de Pneumologie, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicêtre, France.
5
5 INSERM UMR_S 999, Hôpital Marie Lannelongue, Le Plessis Robinson, France; and.
6
6 Weill Cornell Medical College, Institute of Academic Medicine, Houston Methodist Hospital, Houston, Texas.
PMID:
29256625
DOI:
10.1164/rccm.201709-1840PP
No abstract available
Publication types
Review
MeSH terms
Clinical Trials as Topic*
Goals
Humans
Hypertension, Pulmonary / diagnosis*
Hypertension, Pulmonary / physiopathology*
Hypertension, Pulmonary / therapy
Male
Middle Aged
Research Design*